April 16, 2018 / 10:03 AM / 7 months ago

BRIEF-G1 Therapeutics Announces Initiation Of Phase 1B/2 Clinical Trial Of G1T38 In Combination With Tagrisso

April 16 (Reuters) - G1 Therapeutics Inc:

* G1 THERAPEUTICS ANNOUNCES INITIATION OF PHASE 1B/2 CLINICAL TRIAL OF G1T38 IN COMBINATION WITH TAGRISSO FOR EGFR-MUTANT NON-SMALL CELL LUNG CANCER

* G1 THERAPEUTICS INC - ASTRAZENECA IS PROVIDING TAGRISSO FOR PHASE 1B/2 CLINICAL TRIAL UNDER NON-EXCLUSIVE CLINICAL TRIAL COLLABORATION AGREEMENT

* G1 THERAPEUTICS - OPEN-LABEL TRIAL IS EXPECTED TO ENROLL APPROXIMATELY 145 PARTICIPANTS IN TWO PARTS Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below